Legal & General Group’s Progenics Pharmaceuticals Inc PGNX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q2 | – | Sell |
-226,016
| Closed | -$859K | – | 3537 |
|
|
2020
Q1 | $859K | Sell |
226,016
-574
| -0.3% | -$2.47K | ﹤0.01% | 1897 |
|
|
2019
Q4 | $1.15M | Buy |
226,590
+16,891
| +8% | +$89.3K | ﹤0.01% | 2021 |
|
|
2019
Q3 | $1.06M | Buy |
209,699
+12,262
| +6% | +$61.2K | ﹤0.01% | 1969 |
|
|
2019
Q2 | $1.22M | Hold |
197,437
| – | – | ﹤0.01% | 1897 |
|
|
2019
Q1 | $916K | Buy |
197,437
+18,218
| +10% | +$82.4K | ﹤0.01% | 1990 |
|
|
2018
Q4 | $744K | Hold |
179,219
| – | – | ﹤0.01% | 2000 |
|
|
2018
Q3 | $1.12M | Buy |
179,219
+33,799
| +23% | +$260K | ﹤0.01% | 1921 |
|
|
2018
Q2 | $1.17M | Buy |
145,420
+15,320
| +12% | +$117K | ﹤0.01% | 1880 |
|
|
2018
Q1 | $966K | Buy |
130,100
+443
| +0.3% | +$2.95K | ﹤0.01% | 1898 |
|
|
2017
Q4 | $771K | Buy |
129,657
+3,331
| +3% | +$20.2K | ﹤0.01% | 1980 |
|
|
2017
Q3 | $929K | Sell |
126,326
-1,097
| -0.9% | -$6.97K | ﹤0.01% | 1892 |
|
|
2017
Q2 | $866K | Buy |
127,423
+10,947
| +9% | +$80.8K | ﹤0.01% | 1875 |
|
|
2017
Q1 | $1.1M | Buy |
116,476
+99,267
| +577% | +$991K | ﹤0.01% | 1761 |
|
|
2016
Q4 | $150K | Buy |
17,209
+5,525
| +47% | +$40.8K | ﹤0.01% | 2342 |
|
|
2016
Q3 | $70K | Sell |
11,684
-1,106
| -9% | -$6.69K | ﹤0.01% | 2371 |
|
|
2016
Q2 | $53K | Hold |
12,790
| – | – | ﹤0.01% | 2455 |
|
|
2016
Q1 | $55K | Hold |
12,790
| – | – | ﹤0.01% | 2371 |
|
|
2015
Q4 | $79K | Hold |
12,790
| – | – | ﹤0.01% | 2221 |
|
|
2015
Q3 | $71K | Hold |
12,790
| – | – | ﹤0.01% | 2244 |
|
|
2015
Q2 | $89K | Hold |
12,790
| – | – | ﹤0.01% | 2203 |
|
|
2015
Q1 | $76K | Hold |
12,790
| – | – | ﹤0.01% | 2222 |
|
|
2014
Q4 | $93K | Hold |
12,790
| – | – | ﹤0.01% | 2026 |
|
|
2014
Q3 | $65K | Buy |
+12,790
| New | +$63.7K | ﹤0.01% | 2232 |
|
Other funds holding PGNX
Legal & General Group's PGNX Position: Q2 2020 in Review
Legal & General Group sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2020, closing a stake of 226,016 shares — an estimated $859K sold.
Legal & General Group first reported a position in PGNX in Q3 2014 and held it in 23 quarters. The position peaked at $1.22M in Q2 2019. 3 funds tracked by Wall St. Rank hold PGNX as of Q2 2020.
- Legal & General Group reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
- Legal & General Group sold 226,016 Progenics Pharmaceuticals Inc shares in Q2 2020, an estimated $859K.
- Legal & General Group first reported a position in Progenics Pharmaceuticals Inc in Q3 2014 and held it in 23 quarters.
- Legal & General Group's Progenics Pharmaceuticals Inc position peaked at $1.22M in Q2 2019.
- 3 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2020.
Based on Legal & General Group's 13F filing for Q2 2020, filed 14 Aug 2020.